GlassScriptPhysician profile
Michael Rhodes
NPI 1396499935
$11,800.28
in general payments reported to CMS, 2019-2025
38 companies · $3,505 in 2025
The $3,505 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $875 · 2023: $3,469 · 2024: $3,952 · 2025: $3,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $42.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,883.24 |
| Education | $42.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,736.59 | 2022-2025 | |
| Amgen INC. | $1,943.97 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Ucb, INC. | $1,622.16 | 2022-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $563.50 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $526.69 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $512.96 | 2022-2025 | Taltz |
| Radius Health, INC. | $350.32 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.66 | 2023-2025 | Cyltezo, Ofev, Spevigo |
| Janssen Biotech, INC. | $306.05 | 2022-2025 | Tremfya |
| Horizon Therapeutics Plc | $270.28 | 2022-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $247.88 | 2022-2024 | Lupkynis |
| Organon LLC | $241.31 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $239.61 | 2024-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $229.53 | 2022-2025 | Acthar |
| Glaxosmithkline, LLC. | $181.26 | 2023-2025 | Benlysta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $141.65 | 2023-2025 | Idacio, Tyenne |
| Octapharma USA, INC. | $130.76 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Alexion Pharmaceuticals, INC. | $111.66 | 2022-2024 | Strensiq |
| Sobi, INC | $110.58 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $108.28 | 2023-2024 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $93.71 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $92.63 | 2022-2024 | Euflexxa |
| Genzyme Corporation | $87.57 | 2023-2025 | |
| Kyowa Kirin, INC. | $74.76 | 2023-2025 | Crysvita |
| Almatica Pharma LLC | $63.94 | 2024-2025 | Teriparatide |
| Teva Pharmaceuticals USA, INC. | $61.90 | 2023-2024 | Truxima |
| Novo Nordisk INC | $54.87 | 2022 | |
| Genentech USA, INC. | $52.94 | 2024-2025 | Actemra |
| Fidia Pharma USA INC. | $48.58 | 2022-2025 | Hymovis |
| Scilex Pharmaceuticals INC. | $47.50 | 2024 | |
| Biocon Biologics INC | $43.50 | 2024 | Hulio |
| Celltrion USA INC. | $42.33 | 2023 | Yuflyma |
| Medtronic, INC. | $25.79 | 2022 | |
| Mylan Institutional INC. | $25.71 | 2023 | Hulio |
| Abbott Laboratories | $20.96 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.02 | 2025 | Keveyis |
| Boston Scientific Corporation | $17.58 | 2023 | Ams 700 |
| Sandoz INC. | $17.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.